- Home
- MNPR vs HBIO Comparison
MNPR vs HBIO Comparison
Compare MNPR & HBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MNPR
- HBIO
- Stock Information
- Founded
- MNPR 2014
- HBIO 1901
- Country
- MNPR United States
- HBIO United States
- Employees
- MNPR N/A
- HBIO N/A
- Industry
- MNPR Biotechnology: Pharmaceutical Preparations
- HBIO Biotechnology: Laboratory Analytical Instruments
- Sector
- MNPR Health Care
- HBIO Industrials
- Exchange
- MNPR Nasdaq
- HBIO Nasdaq
- Market Cap
- MNPR 95.5M
- HBIO 106.4M
- IPO Year
- MNPR 2019
- HBIO 2000
- Fundamental
- Price
- MNPR $18.09
- HBIO $2.14
- Analyst Decision
- MNPR Strong Buy
- HBIO
- Analyst Count
- MNPR 3
- HBIO 0
- Target Price
- MNPR $27.33
- HBIO N/A
- AVG Volume (30 Days)
- MNPR 1.5M
- HBIO 148.4K
- Earning Date
- MNPR 11-08-2024
- HBIO 11-07-2024
- Dividend Yield
- MNPR N/A
- HBIO N/A
- EPS Growth
- MNPR N/A
- HBIO N/A
- EPS
- MNPR N/A
- HBIO N/A
- Revenue
- MNPR N/A
- HBIO $97,732,000.00
- Revenue This Year
- MNPR N/A
- HBIO N/A
- Revenue Next Year
- MNPR N/A
- HBIO N/A
- P/E Ratio
- MNPR N/A
- HBIO N/A
- Revenue Growth
- MNPR N/A
- HBIO N/A
- 52 Week Low
- MNPR $1.37
- HBIO $2.12
- 52 Week High
- MNPR $38.50
- HBIO $5.56
- Technical
- Relative Strength Index (RSI)
- MNPR 60.19
- HBIO 40.90
- Support Level
- MNPR $16.26
- HBIO $2.30
- Resistance Level
- MNPR $19.70
- HBIO $2.61
- Average True Range (ATR)
- MNPR 2.15
- HBIO 0.15
- MACD
- MNPR -0.07
- HBIO -0.02
- Stochastic Oscillator
- MNPR 74.36
- HBIO 2.86
About MNPR Monopar Therapeutics Inc.
Monopar Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients. The company's pipeline consists of Validive for the prevention of chemoradiotherapy-induced severe oral mucositis in oropharyngeal cancer patients, camsirubicin for the treatment of soft tissue sarcoma, a late-stage preclinical antibody, MNPR-101, for cancers and severe COVID-19 and an early-stage camsirubicin analog, MNPR-202, for various cancers.
About HBIO Harvard Bioscience Inc.
Harvard Bioscience Inc is a developer, manufacturer, and seller of technologies, specialized products and services that enable fundamental research, discovery, and pre-clinical testing for drug development. Its primary focus is scientific instruments used to advance life sciences and research. With operations in North America, Europe and china it sells through a combination of direct and distribution channels to customers around the world. The product brands of the company include Harvard Apparatus, DSI, Buxco, Biochrom, BTX, Heka, Hugo Sachs, Multichannel Systems MCS GmbH, and Panlab.. The majority of its revenue comes from the United States.